C
Cosmecca Korea Co Ltd
KOSDAQ:241710
Cosmecca Korea Co Ltd
KOSDAQ:241710
Price:
90 500
KRW
4.02%
Market Closed
Market Cap:
966.5B
KRW
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
Alert
Cosmecca Korea Co Ltd
90500
+3500 (+4.02%)
| 52 Week Range |
24 900
90 500
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
Abbvie Inc
NYSE:ABBV
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Realty Income Corp
NYSE:O
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
Cosmecca Korea Co Ltd
Balance Sheet
Balance Sheet Decomposition
Cosmecca Korea Co Ltd
Cosmecca Korea Co Ltd
| Current Assets | 254.2B |
| Cash & Short-Term Investments | 48.1B |
| Receivables | 136.8B |
| Other Current Assets | 69.3B |
| Non-Current Assets | 233.1B |
| Long-Term Investments | 2.6B |
| PP&E | 179.8B |
| Intangibles | 36.4B |
| Other Non-Current Assets | 14.2B |
| Current Liabilities | 180.1B |
| Accounts Payable | 54.3B |
| Accrued Liabilities | 2.7B |
| Short-Term Debt | 63.7B |
| Other Current Liabilities | 59.4B |
| Non-Current Liabilities | 111.9B |
| Long-Term Debt | 22.9B |
| Other Non-Current Liabilities | 89B |
Balance Sheet
Cosmecca Korea Co Ltd
Cosmecca Korea Co Ltd
Currency: KRW
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
1 725
|
3 212
|
50 037
|
38 190
|
13 310
|
15 586
|
31 435
|
30 097
|
26 018
|
32 941
|
|
| Cash |
0
|
3 685
|
50 303
|
38 458
|
13 404
|
15 591
|
31 440
|
30 143
|
26 130
|
32 943
|
|
| Cash Equivalents |
1 725
|
473
|
266
|
268
|
94
|
5
|
5
|
46
|
113
|
2
|
|
| Short-Term Investments |
2 373
|
2 457
|
405
|
0
|
0
|
350
|
350
|
0
|
350
|
6 500
|
|
| Total Receivables |
9 806
|
23 801
|
33 518
|
34 152
|
55 981
|
58 005
|
54 204
|
82 038
|
86 075
|
113 811
|
|
| Accounts Receivables |
9 315
|
23 360
|
30 877
|
31 518
|
51 993
|
56 788
|
49 401
|
75 509
|
80 340
|
108 917
|
|
| Other Receivables |
491
|
441
|
2 641
|
2 634
|
3 988
|
1 217
|
4 803
|
6 530
|
5 735
|
4 893
|
|
| Inventory |
5 306
|
9 905
|
15 226
|
15 406
|
47 247
|
49 254
|
59 783
|
66 959
|
71 176
|
65 643
|
|
| Other Current Assets |
473
|
403
|
2 211
|
2 778
|
5 912
|
15 264
|
4 028
|
4 168
|
3 139
|
2 319
|
|
| Total Current Assets |
19 682
|
39 779
|
101 397
|
90 527
|
122 450
|
138 460
|
149 800
|
183 262
|
186 758
|
221 214
|
|
| PP&E Net |
25 457
|
25 926
|
37 916
|
53 195
|
136 331
|
158 620
|
156 231
|
155 025
|
155 006
|
159 098
|
|
| PP&E Gross |
25 457
|
25 926
|
37 916
|
53 195
|
136 331
|
158 620
|
156 231
|
155 025
|
155 006
|
159 098
|
|
| Accumulated Depreciation |
5 819
|
7 953
|
10 508
|
12 960
|
28 189
|
38 909
|
48 699
|
59 146
|
68 460
|
81 303
|
|
| Intangible Assets |
308
|
676
|
668
|
3 241
|
19 047
|
13 104
|
11 627
|
9 429
|
7 192
|
4 808
|
|
| Goodwill |
0
|
0
|
0
|
0
|
33 004
|
33 018
|
33 004
|
33 004
|
33 004
|
33 004
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1 085
|
|
| Long-Term Investments |
3 359
|
1 732
|
1 747
|
1 937
|
2 198
|
1 993
|
2 177
|
2 248
|
2 580
|
2 574
|
|
| Other Long-Term Assets |
2 162
|
1 777
|
1 318
|
2 161
|
2 006
|
5 715
|
6 124
|
8 602
|
8 216
|
10 842
|
|
| Other Assets |
0
|
0
|
0
|
0
|
33 004
|
33 018
|
33 004
|
33 004
|
33 004
|
33 004
|
|
| Total Assets |
50 967
N/A
|
69 890
+37%
|
143 046
+105%
|
151 059
+6%
|
315 035
+109%
|
350 910
+11%
|
358 963
+2%
|
391 569
+9%
|
392 756
+0%
|
432 626
+10%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
10 053
|
20 551
|
22 579
|
21 869
|
29 699
|
34 835
|
29 701
|
30 364
|
34 173
|
44 125
|
|
| Accrued Liabilities |
100
|
152
|
954
|
1 583
|
2 516
|
1 707
|
1 935
|
2 204
|
1 983
|
2 419
|
|
| Short-Term Debt |
11 982
|
12 315
|
2 400
|
2 139
|
23 040
|
36 787
|
41 721
|
60 749
|
65 955
|
56 782
|
|
| Current Portion of Long-Term Debt |
2 000
|
700
|
0
|
0
|
6 378
|
18 964
|
46 368
|
16 339
|
17 626
|
23 050
|
|
| Other Current Liabilities |
4 363
|
6 756
|
10 340
|
9 120
|
17 605
|
17 590
|
21 711
|
25 751
|
23 253
|
28 201
|
|
| Total Current Liabilities |
28 498
|
40 473
|
36 274
|
34 711
|
79 239
|
109 883
|
141 437
|
135 407
|
142 989
|
154 577
|
|
| Long-Term Debt |
3 280
|
5 080
|
0
|
0
|
50 549
|
56 410
|
35 464
|
50 778
|
37 370
|
28 891
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
6 330
|
5 358
|
4 405
|
4 334
|
2 744
|
5 461
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
46 641
|
44 695
|
42 800
|
54 088
|
60 369
|
72 637
|
|
| Other Liabilities |
1 157
|
1 471
|
1 933
|
2 880
|
7 300
|
6 848
|
5 099
|
4 713
|
2 629
|
1 527
|
|
| Total Liabilities |
32 936
N/A
|
47 024
+43%
|
38 207
-19%
|
37 591
-2%
|
190 060
+406%
|
223 194
+17%
|
229 205
+3%
|
249 320
+9%
|
246 102
-1%
|
263 092
+7%
|
|
| Equity | |||||||||||
| Common Stock |
2 000
|
2 000
|
2 670
|
2 670
|
5 340
|
5 340
|
5 340
|
5 340
|
5 340
|
5 340
|
|
| Retained Earnings |
15 933
|
20 721
|
32 054
|
41 410
|
49 010
|
52 837
|
55 419
|
75 058
|
77 887
|
100 230
|
|
| Additional Paid In Capital |
0
|
0
|
70 190
|
70 190
|
71 656
|
69 434
|
69 964
|
55 133
|
55 133
|
55 133
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3 239
|
3 239
|
3 239
|
|
| Other Equity |
99
|
145
|
75
|
801
|
1 031
|
104
|
965
|
3 479
|
5 055
|
5 591
|
|
| Total Equity |
18 032
N/A
|
22 865
+27%
|
104 839
+359%
|
113 469
+8%
|
124 975
+10%
|
127 715
+2%
|
129 759
+2%
|
142 250
+10%
|
146 654
+3%
|
169 533
+16%
|
|
| Total Liabilities & Equity |
50 967
N/A
|
69 890
+37%
|
143 046
+105%
|
151 059
+6%
|
315 035
+109%
|
350 910
+11%
|
358 963
+2%
|
391 569
+9%
|
392 756
+0%
|
432 626
+10%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
8
|
8
|
11
|
11
|
11
|
11
|
11
|
11
|
11
|
11
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
